UNSPSC 51391726: Orciprenaline or metaproterenol

This classification denotes a bronchodilator with the molecular formula C11H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53QOG569E0, chemically known as 3,5-dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol but generally known as metaproterenol, which bears US NIH Compound Identifier 4086. European Medicines Agency schedules Metaproterenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09457MIG. The term METAPROTERENOL is an International Non-Proprietary Name.

World Health Organization schedules metaproterenol in its Anatomical Therapeutic Chemical (ATC) Classification. Orciprenaline or metaproterenol bears US NLM identifiers UMLS ID C0029193 and NCI Concept Code C61834. SMILES: CC(C)NCC(C1=CC(=CC(=C1)O)O)O.

UNSPSC 51391726 Orciprenaline or metaproterenol is a Commodity code that, based on recent state and local activity, encompasses procurement of respiratory bronchodilators and related pharmaceutical products for public health agencies and health and human services departments. The recent opportunities show state and local governments buying naloxone (an opioid antagonist used in overdose response) and related pharmaceutical distribution systems, though the code's nominal scope suggests respiratory medications. County health departments and state health and human services commissions are the primary issuing bodies, with procurement occurring through both competitive sealed bidding (IFB) and information-gathering vehicles (RFI) designed to establish vendor capabilities and market intelligence before formal solicitation.

Activity is concentrated in the South, with Seminole County, Florida posting an IFB (IFB60459723LAS) on June 30, 2026, to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023, and the Texas Health and Human Services Commission issuing an RFI (HHS0017013) on April 3, 2026, to gather information on direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and wholesalers. The Seminole County opportunity specifies a two-year initial contract term with one-year renewal option, fixed-fee pricing, and standard compliance requirements including E-Verify and drug-free workplace certification. The Texas RFI is exploratory, designed to inform future formal procurement strategy around negotiated net pricing models and value-based pharmaceutical contracting, with no award value or binding timeline specified at the RFI stage.